Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
![Angiocrine Bioscience logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/12/Angiocrine_Bioscience_Inc_Logo-1024x502.jpg)
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]
Aflac and Be The Match partner to help diversify the National Blood Stem Cell Donor Registry and improve health equity
![Aflac logo](https://nationalstemcelltherapy.com/wp-content/uploads/2022/09/AFLAC_Logo-1024x357.jpg)
COLUMBUS, Ga. and MINNEAPOLIS, Sept. 8, 2022 /PRNewswire/ — Highlighting its 27-year commitment to children and families facing childhood cancer and sickle cell disease (SCD), Aflac, the number one provider of supplemental health insurance in the U.S.1 and Be The Match®, operated by the National Marrow Donor Program, which has helped facilitate more than 111,000 […]
Autologous Stem Cell Transplants for Blood Cancer Patients
![autologous stem cell transplants for blood cancer patients](https://nationalstemcelltherapy.com/wp-content/uploads/2022/06/autologous-stem-cell-transplants-for-blood-cancer-patients-1024x576.jpg)
This animated video explains the purpose and procedure of Autologous Stem Cell Transplants for blood cancer patients. Video Transcript: Autologous stem cell transplants are a type of treatment for certain blood cancers that require very high doses of chemotherapy or radiation to treat their disease. Chemotherapy or chemo may kill cancer cells, but it also […]